LBRX — LB PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1691082 ·
Last close
$32.95
Market Cap
$944.90M
52W High
$35.35
52W Low
$24.27
ADV30
306,802
Next earnings
2026-05-15
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,104,000 | -19,054,000 | 393,482,000 | 320,676,000 | 14,789,000 |
| Dec 2025 | 0 | — | -13,870,000 | -11,472,000 | 312,934,000 | 250,173,000 | 11,624,000 |
| Sep 2025 | 0 | — | -5,246,000 | -3,556,000 | 320,746,000 | 269,744,000 | 10,525,000 |
| Jun 2025 | — | — | — | — | 19,248,000 | 14,225,000 | 123,121,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-50,370,000
Investing CF
$-44,899,000
Financing CF
$396,393,000
CapEx
$-331,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.97
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-148,582,000
Inventory
—
Receivables
—
ST Investments
$44,960,000
EBIT TTM
$-46,079,000
Pretax Income TTM
$-38,952,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -30,404,000 | -25,205,000 | 312,934,000 | 11,624,000 | — | -35,208,000 |
| Dec 2024 | 0 | -64,830,000 | -63,102,000 | 33,534,000 | 128,088,000 | — | -53,052,000 |
| Dec 2023 | 0 | -11,376,000 | -6,275,000 | 45,657,000 | 80,130,000 | — | -12,094,000 |
| Dec 2022 | 0 | -2,809,000 | -14,348,000 | 21,492,000 | 50,304,000 | — | -2,728,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.41
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $22.50 · spot: $32.95 · call volume: 20 · put volume: 2Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABUS | Arbutus Biopharma Corp | $948.18M | $4.80 | — |
| DSGN | Design Therapeutics, Inc. | $948.72M | $15.19 | — |
| ANNX | Annexon, Inc. | $950.29M | $5.80 | — |
| ANRO | Alto Neuroscience, Inc. | $929.29M | $26.48 | — |
| GERN | GERON CORP | $962.28M | $1.50 | — |
News headlines (Yahoo Finance, 1h cache)
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
2026-07-10 20:38 · Yahoo
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
2026-07-02 20:06 · Yahoo
LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations
2026-06-30 12:00 · Yahoo
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
2026-06-08 11:16 · Yahoo
LB Pharmaceuticals to Participate in Upcoming June Investor Events
2026-05-28 20:05 · Yahoo
All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy
2026-05-26 16:00 · Yahoo
LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans
2026-05-14 11:02 · Yahoo
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-12 20:05 · Yahoo
LB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
2026-04-22 20:05 · Yahoo
LB Pharmaceuticals Highlights LB-102 Phase 3 Schizophrenia Path, Funding Runway to 2029 at Needham
2026-04-17 02:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.